Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

347 ARTÍCULOS , VIENDO DEL 226 AL 240

Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease

Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Soininen H, Thein S, Shiovitz T, Pilcher G, Colby S, Rollin L, Dockens R, Pachai C, Portelius E, Andreasson U, Blennow K, Soares H, Albright C, Feldman HH, Berman RM.

Arch Neurol. 2012 Nov;69(11):1430-40. doi: 10.1001/archneurol.2012.2194.

The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results

Amenta F, Carotenuto A, Fasanaro AM, Rea R, Traini E.

J Neurol Sci. 2012 Nov 15;322(1-2):96-101. doi: 10.1016/j.jns.2012.07.003. Epub 2012 Sep 7.

Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease

Munro CA, Longmire CF, Drye LT, Martin BK, Frangakis CE, Meinert CL, Mintzer JE, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG; Depression in Alzheimer’s Disease Study–2 Research Group.

Am J Geriatr Psychiatry. 2012 Dec;20(12):1036-44. doi: 10.1097/JGP.0b013e31826ce4c5.

Potential of drug-loaded nanoparticles for Alzheimer's disease: diagnosis, prevention and treatment

Doggui S, Dao L, Ramassamy C.

Ther Deliv. 2012 Sep;3(9):1025-7. doi: 10.4155/tde.12.84.

Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort

Wattmo C, Wallin AK, Minthon L.

BMC Neurol. 2012 Nov 5;12:134. doi: 10.1186/1471-2377-12-134.

Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial

Egefjord L, Gejl M, Møller A, Brændgaard H, Gottrup H, Antropova O, Møller N, Poulsen HE, Gjedde A, Brock B, Rungby J.

Dan Med J. 2012 Oct;59(10):A4519.

Practice effects in a longitudinal, multi-center Alzheimer's disease prevention clinical trial

Abner EL, Dennis BC, Mathews MJ, Mendiondo MS, Caban-Holt A, Kryscio RJ, Schmitt FA; PREADViSE Investigators; Crowley JJ; SELECT Investigators.

Trials. 2012 Nov 20;13:217. doi: 10.1186/1745-6215-13-217.

[Nanoparticles for brain delivery of drugs or contrast agents. Application to Alzheimer's disease]

Andrieux K, Couvreur P.

Biol Aujourdhui. 2012;206(3):185-90. doi: 10.1051/jbio/2012019. Epub 2012 Nov 22.

[Alzheimer's disease: are non-steroidal anti-inflammatory drugs effective?]

Peters O.

Dtsch Med Wochenschr. 2012 Dec;137(50):2627. doi: 10.1055/s-0032-1329138. Epub 2012 Dec 5.

[Assessment of benefits of drug therapies: memantine for Alzheimer's disease as an example]

Rüther E, Hellweg R, Janetzky W.

Fortschr Neurol Psychiatr. 2012 Dec;80(12):694-9. doi: 10.1055/s-0032-1312976. Epub 2012 Dec 10.

[Effects of telmisartan on the level of Aβ1-42, interleukin-1β, tumor necrosis factor α and cognition in hypertensive patients with Alzheimer's disease]

Li W, Zhang JW, Lu F, Ma MM, Wang JQ, Suo AQ, Bai YY, Liu HQ.

Zhonghua Yi Xue Za Zhi. 2012 Oct 23;92(39):2743-6.

The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design

Devanand DP, Mintzer J, Schultz S, Sultzer D, de la Pena D, Gupta S, Colon S, Schimming C, Pelton GH, Andrews H, Levin B.

Am J Geriatr Psychiatry. 2012 Apr;20(4):362-73. doi: 10.1097/JGP.0b013e3182110563.

Effects of atorvastatin on cerebral blood flow in middle-aged adults at risk for Alzheimer's disease: a pilot study

Carlsson CM, Xu G, Wen Z, Barnet JH, Blazel HM, Chappell RJ, Stein JH, Asthana S, Sager MA, Alsop DC, Rowley HA, Fain SB, Johnson SC.

Curr Alzheimer Res. 2012 Oct;9(8):990-7. doi: 10.2174/156720512803251075.

A systematic review of adverse events in the placebo arm of donepezil trials: the role of cognitive impairment

Amanzio M, Benedetti F, Vase L.

Int Psychogeriatr. 2012 May;24(5):698-707. doi: 10.1017/S1041610211002420. Epub 2012 Jan 4.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias